US-based Agilent Technologies has introduced its new comparative genomic hybridisation (CGH) assay for use in diagnostic purposes.

Named GenetiSure Dx Postnatal assay, the new device will help clinical geneticists to detect genetic anomalies earlier and more accurately than traditional methods.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The assay is also designed to detect various anomalies, which are related to the developmental delay, intellectual disability, autism, congenital irregularities and dysmorphic features in children and adults.

"From DNA to data analysis, this assay allows for easy implementation into the clinical routine."

Incorporating CGH technology into diagnostics, the GenetiSure Dx Postnatal assay has been developed on the basis of Agilent's collection for comparative genomic hybridisation.

It will also provide data on copy number variations and in absence of heterozygosity, and will carry CE marking for in vitro diagnostics.

In addition, the assay will help identify genetic diagnosis, enabling faster investigation and offering appropriate medical care.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Agilent Technologies genomics solutions division and clinical applications division vice-president and general manager Herman Verrelst said: “The GenetiSure Dx Postnatal Assay has been developed for cytogenetic laboratories, combining high-quality data with easy laboratory setup and streamlined protocols.

“From DNA to data analysis, this assay allows for easy implementation into the clinical routine.”

In October last year, the company launched SureGuide CRISPR libraries for use in functional genomics.

SureGuide features Agilent's oligonucleotide synthesis platform to create clustered regularly interspaced short palindromic repeats (CRISPR) guide libraries, which are a critical component of the CRISPR / Cas genome editing system.